STX-478-101

BMS CA244-0001

MK-3120-002-00

DS2243-054

REGN7075

F60089IV101

IMA402-101

PANTUMOR 1479-0009

222730

ANV600-001

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

STX-721-101

D6900C00001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors.



<ul class="wp-block-list">
<li>Code NKI: M24IMA</li>



<li>Code firma: IMA402-101</li>



<li>Code clinicaltrials.gov: NCT05958121</li>
</ul>



Principal Investigator



Dr. T. Schutte



Drugs 



IMA402; a Bispecific T Cell-Engaging Receptor Molecule targeting PRAME



<h2 class="wp-block-heading">Summary</h2>



The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.



Read more on <a href="https://clinicaltrials.gov/study/NCT05958121?term=NCT05958121&amp;rank=1" data-type="link" data-id="https://clinicaltrials.gov/study/NCT06043817?term=First-In-Human%20Study%20of%20STX-721%20in%20Participants%20With%20Locally%20Advanced%20or%20%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer%20Harboring%20EGFR%20Exon%2020%20Insertion%20%20Mutations&amp;rank=1">clinicaltrials.gov</a>.



<h2 class="wp-block-heading">Additional comments</h2>



<ul class="wp-block-list">
<li>Dose escalation: melanoma &#8211; open</li>



<li>Dose escalation: endometrial &#8211; open</li>



<li>Dose escalation: ovarian &#8211; closed</li>
</ul>